NEULANDLAB.NS Stock Analysis
NE
Avoid
Based on Eyestock quantitative analysis, NEULANDLAB.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Neuland Laboratories Ltd. engages in the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company is headquartered in Hyderabad, Telangana and currently employs 1,573 full-time employees. The firm caters to both domestic and international markets. The company manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The firm provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The firm operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The firm has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.